Evidence map›Paper›PMID 42565867›Full record

Observational studyJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2026

Hepatitis A vaccination during ventricular assist device support in heart transplant candidates: immunogenicity and safety in a single-center cohort.

Masahiro Arima, Shinya Yamamoto, Maho Adachi-Katayama, Koh Okamoto, Masahiko Ando, Shu Okugawa, Minoru Ono, Takeya Tsutsumi

Abstract readObservational Study
In one paragraph

Observational study in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masahiro ArimaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Shinya YamamotoDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan. shinyayamamoto@g.ecc.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0003-2890-7256
Maho Adachi-KatayamaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8960-8212
Koh OkamotoDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4072-9096
Masahiko AndoDepartment of Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Shu OkugawaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3455-8291
Minoru OnoDepartment of Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Takeya TsutsumiDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0851-1887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is among the cornerstones of infectious disease prevention in heart transplant candidates and recipients. Guidelines recommend an inactivated hepatitis A virus vaccine for heart transplant candidates, many of whom are on ventricular assist devices and at risk of hepatitis A virus exposure. However, data on the immunogenicity and safety of hepatitis A virus vaccines in these patients are lacking.This retrospective, observational, single-center study was conducted at our outpatient clinic between December 2019 and December 2025. The study participants were heart transplant candidates with ventricular assist devices aged ≥16 years who tested negative for anti-hepatitis A virus immunoglobulin G at baseline and completed the inactivated hepatitis A virus vaccination series. Anti-hepatitis A virus immunoglobulin G titers were measured after vaccination using a chemiluminescent immunoassay. Thirty-five individuals were included in the study. Immunosuppressive agents were used in four patients (11.4%). All participants achieved seroconversion at a median of 1 month after vaccination. The reverse cumulative distribution of the Anti-hepatitis A virus immunoglobulin G sample/cutoff values indicated that an adequate antibody response was achieved in individuals with ventricular assist devices. Adverse events of the vaccine were minor; two patients (6%) experienced local pain, and two (6%) subcutaneous hemorrhage. Seroconversion in patients with ventricular assist devices was high. hepatitis A virus vaccination should be completed before transplantation in heart transplant candidates, if indicated.

Indexed as

Heart-Assist DevicesHeart TransplantationHepatitis AHepatitis A VaccinesAdultAgedFemaleHepatitis A AntibodiesHumansImmunoglobulin GMaleMiddle AgedRetrospective StudiesVaccinationHepatitis A AntibodiesHepatitis A VaccinesImmunoglobulin GArtificial heartHeart transplantationHepatitis A vaccineVentricular assist device

Identifiers

PMID42565867
PMCPMC13451224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.